2024
Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial
Ramakrishnan D, Brüningk S, von Reppert M, Memon F, Maleki N, Aneja S, Kazerooni A, Nabavizadeh A, Lin M, Bousabarah K, Molinaro A, Nicolaides T, Prados M, Mueller S, Aboian M. Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial. American Journal Of Neuroradiology 2024, 45: 475-482. PMID: 38453411, PMCID: PMC11288571, DOI: 10.3174/ajnr.a8189.Peer-Reviewed Original ResearchArea under the curvePediatric gliomasBT-RADSResponse assessmentPartial responseClinical trialsVolumetric analysisReceiver operating characteristic analysisBrain Tumor ReportingReceiver operating characteristic curveModel estimation timeOperating characteristic analysisEvaluate treatment efficacyStable diseasePartial respondersManual volumetric segmentationNo significant differenceSolid tumorsProspective studyTumor ReportingClinical decision-makingTreatment efficacyGliomaSignificant differenceCharacteristic curve
2020
Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma
Robinson MH, Vasquez J, Kaushal A, MacDonald TJ, Vega J, Schniederjan M, Dhodapkar K. Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. Journal For ImmunoTherapy Of Cancer 2020, 8: e001066. PMID: 32788236, PMCID: PMC7422651, DOI: 10.1136/jitc-2020-001066.Peer-Reviewed Original ResearchConceptsT cell infiltrationHigh-grade gliomasT-cell densityLow-grade tumorsT cellsGlial tumorsTissue-resident memory T cellsTumor-resident T cellsPediatric gliomasTumor-infiltrating T cellsMemory T cellsCancer-related mortalityPediatric glial tumorsSingle-cell mass cytometryExpression of SOX2Stem cell markersImmune controlImmune therapyRecurrent tumorsImmune cellsImmunofluorescence immunohistochemistryPleomorphic xanthoastrocytomaBrain tumorsImmune architectureAdult gliomasComparative Molecular Life History of Spontaneous Canine and Human Gliomas
Amin S, Anderson K, Boudreau C, Martinez-Ledesma E, Kocakavuk E, Johnson K, Barthel F, Varn F, Kassab C, Ling X, Kim H, Barter M, Lau C, Ngan C, Chapman M, Koehler J, Long J, Miller A, Miller C, Porter B, Rissi D, Mazcko C, LeBlanc A, Dickinson P, Packer R, Taylor A, Rossmeisl J, Woolard K, Heimberger A, Levine J, Verhaak R. Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Cancer Cell 2020, 37: 243-257.e7. PMID: 32049048, PMCID: PMC7132629, DOI: 10.1016/j.ccell.2020.01.004.Peer-Reviewed Original ResearchConceptsComparative genomic analysisDNA methylation patternsReceptor tyrosine kinasesCell cycle pathwayGenomic analysisMethylation sequencingLife historyMutational processesTyrosine kinaseHigh similarityHuman gliomasTumorigenic mechanismsHost environmentMutational rateSomatic alterationsSporadic gliomasIDH1 R132Canine gliomasMolecular profileGlioma etiologyHuman pediatricPediatric gliomasTranscriptomeKinaseUnique insights
2019
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma
Fons NR, Sundaram RK, Breuer GA, Peng S, McLean RL, Kalathil AN, Schmidt MS, Carvalho DM, Mackay A, Jones C, Carcaboso ÁM, Nazarian J, Berens ME, Brenner C, Bindra RS. PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. Nature Communications 2019, 10: 3790. PMID: 31439867, PMCID: PMC6706443, DOI: 10.1038/s41467-019-11732-6.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBrain Stem NeoplasmsCell Line, TumorChildCytokinesDiffuse Intrinsic Pontine GliomaDNA MethylationEpigenetic RepressionFemaleGene Expression Regulation, NeoplasticHumansMiceNicotinamide PhosphoribosyltransferasePonsPrimary Cell CultureProtein Phosphatase 2CSynthetic Lethal MutationsXenograft Model Antitumor AssaysConceptsNicotinic acid phosphoribosyltransferaseSynthetic lethal interactionsNAMPT inhibitorsTumor-specific cell killingProtein phosphataseEpigenetic silencingMutant cellsKey genesCpG islandsLethal interactionsNAD biosynthesisGene expressionInhibitor sensitivityNAD metabolismOncogenic rolePediatric gliomasMutationsModel systemCell killingDriver mutationsPediatric high-grade gliomasMutant tumorsOncogenic driver mutationsNicotinamide phosphoribosyltransferase (NAMPT) inhibitionGenomeHGG-11. GERMLINE GENETIC PREDISPOSITION TO PEDIATRIC GLIOMA
Muskens I, Walsh K, Zhang C, de Smith A, Morimoto L, Ma X, Wiemels J. HGG-11. GERMLINE GENETIC PREDISPOSITION TO PEDIATRIC GLIOMA. Neuro-Oncology 2019, 21: ii89-ii89. PMCID: PMC6477444, DOI: 10.1093/neuonc/noz036.105.Peer-Reviewed Original ResearchPediatric glioma patientsGBM patientsGene burden testingGlioma patientsPediatric gliomasPediatric brain tumorsPathogenic germline mutationsPopulation-based sampling strategyGermline genetic predispositionCancer predisposition genesRare germline variantsWhole-exome sequencingTreatment strategiesPractice guidelinesBest practice guidelinesBrain tumorsGenetic predispositionCancer-related genesPatientsTP53 mutationsTP53 variantsGlioma riskFrameshift mutationBlood spotsNonsense mutation
2018
PDTM-01. GERMLINE GENETIC PREDISPOSITION TO PEDIATRIC GLIOMA
Muskens I, Walsh K, de Smith A, Morimoto L, Metayer C, Ma X, Wiemels J. PDTM-01. GERMLINE GENETIC PREDISPOSITION TO PEDIATRIC GLIOMA. Neuro-Oncology 2018, 20: vi203-vi203. PMCID: PMC6217152, DOI: 10.1093/neuonc/noy148.843.Peer-Reviewed Original ResearchPediatric gliomasGenetic predispositionCancer-related genesReceptor tyrosine kinasesPediatric brain tumorsGermline genetic predispositionHigh-grade gliomasPediatric glioma patientsRare germline variantsWhole-exome sequencingRare germline mutationsExome Aggregation Consortium databaseAstrocytoma patientsGlioma patientsBrain tumorsSpecific receptor tyrosine kinasesGrade gliomasHigh mortalityNerve cellsGermline mutationsGermline variantsGliomasTyrosine kinase proteinTranslational implicationsConsortium database
2017
PDTM-25. GENETIC SUSCEPTIBILITY AND EVOLUTION OF PEDIATRIC IDH-MUTANT INFILTRATING ASTROCYTOMAS
Bornhorst M, Goecks J, Boue D, Broniscer A, Hwang E, Koschmann C, Marks A, Mody R, Mueller S, Orr B, Packer R, Solomon D, Turner J, Vortmeyer A, Nazarian J, Ho C. PDTM-25. GENETIC SUSCEPTIBILITY AND EVOLUTION OF PEDIATRIC IDH-MUTANT INFILTRATING ASTROCYTOMAS. Neuro-Oncology 2017, 19: vi195-vi195. PMCID: PMC5692642, DOI: 10.1093/neuonc/nox168.789.Peer-Reviewed Original ResearchTP53 mutationsPediatric gliomasGermline mutationsIDH mutationsLow-grade tumorsHigh-grade tumorsLow mutation burdenYears of ageHigh-grade astrocytomasGermline TP53 mutationsMismatch repair genesIDH-mutant astrocytomasYounger patientsMulti-institution studyEarly lesionsMutation burdenMutant allele frequencyPatientsSporadic casesAstrocytomasTumorsSporadic tumorsAdult counterpartsGenetic susceptibilityLow cellularitySOX2 as a target for immunotherapy of pediatric gliomas.
Vasquez J, Huttner A, Zhang L, Marks A, Chan A, Baehring J, Kahle K, Dhodapkar K. SOX2 as a target for immunotherapy of pediatric gliomas. Journal Of Clinical Oncology 2017, 35: e22012-e22012. DOI: 10.1200/jco.2017.35.15_suppl.e22012.Peer-Reviewed Original ResearchTumor-infiltrating T cellsImmune checkpoint blockadeT cellsPediatric glial tumorsGlial tumorsExpression of SOX2Inhibitory checkpointsCheckpoint blockadeTumor immunityGrade gliomasTissue-resident memory phenotypePediatric gliomasTumor-infiltrating immune cellsTumor cellsResident memory phenotypeT-cell proliferation assaysImmune checkpoint inhibitorsDendritic cell vaccinesPD-1 expressionSubset of CD4Anti-tumor immunityCD8 T cellsT cell immunityEffective tumor immunityPediatric brain tumors
2012
Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy
Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. Journal Of Neuro-Oncology 2012, 111: 103-111. PMID: 23179498, PMCID: PMC3546121, DOI: 10.1007/s11060-012-0998-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overAntigens, NeoplasmBrainBrain NeoplasmsCancer VaccinesChildChild, PreschoolEpendymomaFemaleGene Expression Regulation, NeoplasticHistocompatibility Antigens Class IHumansInfantInhibitor of Apoptosis ProteinsInterleukin-13 Receptor alpha1 SubunitMaleMiddle AgedReceptor, EphA2SurvivinWT1 ProteinsConceptsTumor-associated antigensMore tumor-associated antigensIL-13Rα2Positive stainingAdult ependymomasMultiple peptides vaccineNormal brain tissueGlioma vaccinesImmunotherapy approachesVaccine therapyPediatric casesAdult casesTumor recurrenceClinical trialsPeptide vaccinePediatric ependymomaNormal brainEpendymomaBrain tissuePediatric gliomasTumor 1SurvivinStainingEphA2Vaccine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply